BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

"The third quarter of 2024 was transformative for BioAge as we achieved two major milestones: initiating our Phase 2 STRIDES trial evaluating azelaprag in combination with tirzepatide, and completing ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

The dramatically upsized IPO ties into an increasingly buoyant biotech financing environment, with a string of upsized ...

Drug developers have achieved resounding success in the fall U.S. IPO market, with all the $100-million plus offerings since September upsized. Robust debuts by drug developers Bicara Therapeutics , ...

Meanwhile, BioAge Labs, which went public in late September, is up nearly 40 percent from its IPO price. It sold 11 million shares at $18 apiece, the second time it raised its terms. At least ...

END OF THE WEEK PERFORMANCE: RECENT IPOS TO WATCH: BioAge (BIOA), Innovation Beverage ... UPCOMING IPOS: Upcoming IPO and direct listings expected include Pony AI (PONY), Infinity Natural ...